International Assets Investment Management LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 37,315 shares of the biotechnology company's stock, valued at approximately $3,598,000.
A number of other institutional investors have also added to or reduced their stakes in BMRN. SteelPeak Wealth LLC purchased a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth $217,000. Arizona State Retirement System grew its stake in shares of BioMarin Pharmaceutical by 1.0% in the fourth quarter. Arizona State Retirement System now owns 51,718 shares of the biotechnology company's stock worth $4,987,000 after acquiring an additional 510 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of BioMarin Pharmaceutical by 149.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,156 shares of the biotechnology company's stock worth $2,136,000 after acquiring an additional 13,270 shares during the last quarter. Private Ocean LLC purchased a new stake in shares of BioMarin Pharmaceutical in the fourth quarter worth $140,000. Finally, JGP Global Gestao de Recursos Ltda. grew its stake in shares of BioMarin Pharmaceutical by 15.4% in the fourth quarter. JGP Global Gestao de Recursos Ltda. now owns 3,132 shares of the biotechnology company's stock worth $302,000 after acquiring an additional 419 shares during the last quarter. Institutional investors own 98.71% of the company's stock.
BioMarin Pharmaceutical Stock Performance
Shares of NASDAQ BMRN traded down $0.40 during trading on Thursday, hitting $90.07. The company had a trading volume of 944,850 shares, compared to its average volume of 1,348,617. The stock has a 50 day simple moving average of $87.61 and a 200 day simple moving average of $89.11. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.57 and a current ratio of 2.51. BioMarin Pharmaceutical Inc. has a 12 month low of $76.02 and a 12 month high of $99.56. The firm has a market capitalization of $17.00 billion, a P/E ratio of 102.35, a price-to-earnings-growth ratio of 1.68 and a beta of 0.31.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. BioMarin Pharmaceutical had a return on equity of 5.01% and a net margin of 6.93%. The firm had revenue of $646.21 million for the quarter, compared to the consensus estimate of $639.53 million. During the same quarter last year, the company earned $0.11 earnings per share. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. As a group, analysts anticipate that BioMarin Pharmaceutical Inc. will post 1.85 earnings per share for the current year.
Insider Transactions at BioMarin Pharmaceutical
In related news, insider Henry J. Fuchs sold 35,341 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the sale, the insider now owns 212,117 shares of the company's stock, valued at approximately $18,068,126.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Henry J. Fuchs sold 35,341 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the sale, the insider now owns 212,117 shares of the company's stock, valued at approximately $18,068,126.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jean Jacques Bienaime sold 15,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $88.28, for a total value of $1,324,200.00. Following the completion of the sale, the director now directly owns 419,602 shares in the company, valued at approximately $37,042,464.56. The disclosure for this sale can be found here. Insiders have sold 103,229 shares of company stock valued at $9,062,967 over the last quarter. 1.84% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on BMRN shares. Royal Bank of Canada reissued a "sector perform" rating and issued a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Piper Sandler dropped their price objective on BioMarin Pharmaceutical from $115.00 to $107.00 and set an "overweight" rating on the stock in a research report on Friday, February 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $100.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Stifel Nicolaus reaffirmed a "buy" rating and set a $101.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, December 21st. Finally, Robert W. Baird dropped their price objective on BioMarin Pharmaceutical from $127.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 30th. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $107.61.
Get Our Latest Stock Report on BMRN
About BioMarin Pharmaceutical
(
Free Report)
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Further Reading
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
